Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mitoxantrone: its development and role in clinical practice.

R B Weiss1

  • 1Walter Reed Army Medical Center, Washington, DC.

Oncology (Williston Park, N.Y.)
|June 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defining a transcriptional fingerprint of murine splenic B-cell development.

Genes and immunity·2008
Same author

Duplications in the DMD gene.

Human mutation·2006
Same author

Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort.

American journal of medical genetics. Part A·2005
Same author

Automated genomic sequence analysis of the three collagen VI genes: applications to Ullrich congenital muscular dystrophy and Bethlem myopathy.

Journal of medical genetics·2005
Same author

DNA sequence variation in a 3.7-kb noncoding sequence 5' of the CYP1A2 gene: implications for human population history and natural selection.

American journal of human genetics·2002
Same author

Developmental vulnerabilities to the onset and course of bipolar disorder.

Development and psychopathology·2001

Mitoxantrone is an antitumor drug developed as a doxorubicin alternative with a better therapeutic index. It shows efficacy in various cancers, offering a potentially advantageous toxicity profile for selected patients.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Mitoxantrone was synthesized as a doxorubicin analog.
  • It was designed to improve the therapeutic index compared to doxorubicin.
  • Mitoxantrone exhibits activity against several cancer types.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of mitoxantrone.
  • To compare mitoxantrone with doxorubicin as an antitumor agent.

Main Methods:

  • Clinical assessment of mitoxantrone in patients with acute leukemias, breast carcinoma, non-Hodgkin's lymphoma, and ovarian cancers.
  • Evaluation of cross-resistance patterns with anthracyclines.
  • Comparison of toxicity profiles, including alopecia and administration duration, with doxorubicin.

Main Results:

Related Experiment Videos

  • Mitoxantrone demonstrated clinical activity in acute leukemias, breast carcinoma, non-Hodgkin's lymphoma, and ovarian cancers.
  • A lack of cross-resistance to anthracyclines was observed.
  • Mitoxantrone presented a more favorable toxicity spectrum, with less alopecia and longer administration potential than doxorubicin.

Conclusions:

  • Mitoxantrone can serve as a viable substitute for doxorubicin in specific patient populations.
  • Doxorubicin is expected to remain the more commonly used drug despite mitoxantrone's advantages.